Ganoderic acid D 是一种高度氧化的四环三萜类化合物 (tetracyclic triterpenoid)，是灵芝 (Ganoderma lucidum) 的主要活性成分。Ganoderic acid D 上调SIRT3的蛋白质表达并通过 SIRT3 诱导脱乙酰化的亲环蛋白 D (CypD)。Ganoderic acid D 抑制结肠癌细胞的能量重编程，包括结肠癌细胞中的葡萄糖摄取，乳酸产生，丙酮酸和乙酰辅酶的产生。Ganoderic acid D 诱导 HeLa 人宫颈癌细胞凋亡 (apoptosis)。
| 生物活性 | Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component ofGanoderma lucidum. Ganoderic acid D upregulates the protein expression ofSIRT3and induces the deacetylated cyclophilin D (CypD) bySIRT3. Ganoderic acid D inhibits the energy reprogramming of coloncancercells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in coloncancercells[1]. Ganoderic acid D induces HeLa human cervical carcinomaapoptosis[2]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | Ganoderic acid D can inhibit the growth of numerous cancer cell lines and it inhibits HeLa human cervical carcinoma cells with an IC50of 17.3 mM[2].
Ganoderic acid D (1-50 μM; 24-72 hours) reduces the cell survival rate in a dose- and time-dependent manner[2].
Ganoderic acid D (10, 50 μM; 24, 48 hours) induces G2/M phase arrest[2].
Ganoderic acid D (10, 50 μM; 24, 48 hours) induces a morphological change typical of apoptosis in HeLa cells[2].
Ganoderic acid D (10 μM; 48 hours) up-regulates 14-3-3E and PRDX3[2].
Cell Viability Assay[2] | Cell Line: | HeLa human cervical carcinoma cell line (CCL-2) | | Concentration: | 1, 5, 10, 20, 50 μM | | Incubation Time: | 24, 48, 72 hours | | Result: | Reduced the cell survival rate in a dose- and time-dependent manner and had an IC50value of 17.3 μM for 48 hours treatment. |
Cell Cycle Analysis[2] | Cell Line: | HeLa human cervical carcinoma cell line (CCL-2) | | Concentration: | 10, 50 μM | | Incubation Time: | 24, 48 hours | | Result: | Induced G2/M phase arrest.
Displayed a cell cycle profile with an elevated G2/M cell population after 24-h treatment with 10 μM. |
Apoptosis Analysis[2] | Cell Line: | HeLa human cervical carcinoma cell line (CCL-2) | | Concentration: | 10, 50 μM | | Incubation Time: | 48 hours | | Result: | Induced a morphological change typical of apoptosis in HeLa cells. |
Western Blot Analysis[2] | Cell Line: | HeLa human cervical carcinoma cell line (CCL-2) | | Concentration: | 10 μM | | Incubation Time: | 48 hours | | Result: | Up-regulated 14-3-3E and PRDX3. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | |
| 来源 | - Plants
- Polyporaceae
- Ganoderma lucidum(Leyss. Ex Fr.) Karst.
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 100 mg/mL(194.31 mM;Need ultrasonic) H2O :< 0.1 mg/mL(insoluble) 配制储备液 | 1 mM | 1.9431 mL | 9.7153 mL | 19.4307 mL | | 5 mM | 0.3886 mL | 1.9431 mL | 3.8861 mL | | 10 mM | 0.1943 mL | 0.9715 mL | 1.9431 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.86 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.86 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 3. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.86 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
